+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Triple therapy with daily induction Interferon-alpha2a , Ribavirin and Amantadine for patients with chronic hepatitis C , who failed to respond to a previous combination treatment protocol Single arm open label pilot study Initial response, safety and tolerability



Triple therapy with daily induction Interferon-alpha2a , Ribavirin and Amantadine for patients with chronic hepatitis C , who failed to respond to a previous combination treatment protocol Single arm open label pilot study Initial response, safety and tolerability



Hepatology 32(4 Pt 2): 559A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035987367

Download citation: RISBibTeXText


Related references

The role of triple therapy with amantadine sulphate plus ribavirin and interferon alpha2a on chronic hepatitis c patients. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1258, 2003

The combination of daily interferon-alpha induction dosing and ribavirin in IFN non-responders with chronic hepatitis C Initial response and tolerability. Hepatology 30(4 Part 2): 201A, 1999

Interferon alpha2a induction therapy in combination with ribavirin and amantadine in naive patients with chronic HCV infection. Gastroenterology 120(5 Suppl. 1): A 409, 2001

Safety and efficacy of triple therapy (interferon, ribavirin and amantadine) in the treatment of chronic HCV liver disease patients who have previously failed dual therapy. American Journal of Gastroenterology 95(9): 2516-2516, 2000

Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. Journal of Gastroenterology and Hepatology 19(Suppl. 6): S79-S81, 2004

Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. Journal of Gastroenterology and Hepatology 19(12): S79-S81, 2004

Treatment of hepatitis C with daily induction dose interferon alpha 2b plus ribavirin followed by daily combination therapy in patients who are treatment naive or have previously failed an interferon based therapy. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A146, 2000

Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wiener Klinische Wochenschrift 116(15-16): 530-535, 2004

Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Zeitschrift für Gastroenterologie 39(2): 145-151, 2001

Pilot study of interferon-alfa high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Hepatology 30(4 Part 2): 270A, 1999

Eighteen MU Interferon daily induction therapy in combination with ribavirin and amantadine for patients with a virological relapse of chronic hepatitis C HCV-RNA kinetics and adverse events. Hepatology 32(4 Pt 2): 443A, 2000

HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. Journal of Viral Hepatitis 7(6): 409-413, 2000

Efficacy and tolerability of combination therapy with interferon-alfa plus ribavirin in patients with chronic hepatitis C virus infection: a single-center study in relapsers and nonresponders to previous treatment with high-dose interferon-alfa monotherapy. Current Therapeutic Research Clinical and Experimental 64(3): 140-150, 2003

High response rates to interferon induction plus ribavirin and amantadine in the treatment of interferon nonresponder chronic hepatitis C patients A randomized controlled pilot study. Journal of Hepatology 32(Suppl. 2): 107, 2000

Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. European Journal of Gastroenterology and Hepatology 14(5): 477-483, 2002